Calciphylaxis: risk factors, diagnosis, and treatment.
Calciphylaxis: risk factors, diagnosis, and treatment.
复制标题
DOI：
10.1053/j.ajkd.2015.01.034
复制
发表时间：
2015-07
期刊：
影响因子：
--
通讯作者：
Thadhani RI
中科院分区：
文献类型：
--
作者：
Nigwekar SU;Kroshinsky D;Nazarian RM;Goverman J;Malhotra R;Jackson VA;Kamdar MM;Steele DJ;Thadhani RI
钙质疏松是一种罕见但毁灭性的疾病，自几十年前的科学文献中早期描述以来，一直困扰着医学界。它主要见于接受透析(尿毒症钙剂中毒)治疗的慢性肾功能衰竭患者，但也可见于慢性肾脏疾病早期和肾功能正常的患者。在这篇实践专题中，我们回顾了有关尿毒症和非尿毒症钙质沉着的危险因素、诊断和治疗的现有医学文献。目前尚缺乏高质量的证据来评估和处理钙质疏松，这是由于其罕见的发病率，对其发病机制的了解很少，以及协作研究的努力相对较少。我们在此提供马萨诸塞州总医院多学科钙剂防治小组为钙剂缺乏症患者制定的建议摘要。
Calciphylaxis is a rare but devastating condition that has continued to challenge the medical community since its early descriptions in the scientific literature many decades ago. It is predominantly seen in chronic kidney failure patients treated with dialysis (uremic calciphylaxis) but is also described in patients with earlier stages of chronic kidney disease and with normal renal function. In this In Practice feature, we review the available medical literature regarding risk factors, diagnosis, and treatment of both uremic and non-uremic calciphylaxis. High quality evidence for the evaluation and management of calciphylaxis is lacking at this time due to its rare incidence, poorly understood pathogenesis, and the relative paucity of collaborative research efforts. We hereby provide a summary of recommendations developed by the Massachusetts General Hospital's Multi-disciplinary Calciphylaxis Team for calciphylaxis patients.